Related Experiment Video
Updated: Jan 16, 2026

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
Exosomal miRNAs as biomarkers in predicting chemotherapy-induced cardiotoxicity in patients with cancer (Review)
Vedant Shah1, Viraj Panchal2, Abhi Shah2
1Department of Internal Medicine, The New York Medical College Graduate Medical Education Program at St. Mary's General Hospital and Saint Clare's Health, Denville, NJ 07834, USA.
Abstract:
With the advancements made in oncology, such as molecularly targeted therapies and immune checkpoint inhibitors, their use has significantly improved the outcomes of patients with cancer. In addition, these advancements have led to an increased incidence of cardiotoxicity, ranging from subclinical dysfunction to severe cardiomyopathy. Hence, it is imperative to enable the early detection and prevention of cardiotoxicity to mitigate irreversible cardiac damage. Exosomal microRNAs (miRNAs) have emerged as promising non-invasive biomarkers due to their stability in biological fluids and their ability to reflect early myocardial stress and damage. Unlike traditional biomarkers such as troponins, which indicate damage after myocardial injury has occurred, miRNAs can detect subclinical changes earlier, enabling timely intervention. Exosomal miRNAs not only serve as diagnostic biomarkers, but also provide therapeutic potential by modulating molecular pathways associated with cardiotoxicity. Understanding the regulatory mechanisms of miRNA expression in chemotherapy-induced cardiotoxicity can pave the way for personalized cardioprotective strategies, minimizing cardiovascular complications during cancer therapy. The present review discusses the role of various miRNAs as biomarkers for the early diagnosis of cardiotoxicity induced by chemotherapeutic agents.
Insights
Exosomal microRNAs (miRNAs) show promise for early detection of cancer therapy-related cardiotoxicity. These biomarkers can identify subclinical cardiac changes, enabling timely interventions and personalized cardioprotective strategies.
Area of Science:
- Cardiology
- Oncology
- Biomarkers
Background:
- Cancer therapies like targeted therapies and immune checkpoint inhibitors improve patient outcomes but increase cardiotoxicity risk.
- Cardiotoxicity ranges from subclinical dysfunction to severe cardiomyopathy, necessitating early detection and prevention.
- Traditional biomarkers like troponins indicate damage post-injury, limiting early intervention.
Purpose of the Study:
- To review the role of exosomal microRNAs (miRNAs) as early diagnostic biomarkers for cardiotoxicity induced by chemotherapeutic agents.
- To highlight the potential of exosomal miRNAs in enabling timely intervention and personalized cardioprotective strategies.
- To discuss the therapeutic potential of exosomal miRNAs in modulating cardiotoxicity-related molecular pathways.
Main Methods:
- Literature review focusing on exosomal microRNAs (miRNAs) and their association with chemotherapy-induced cardiotoxicity.
- Analysis of studies investigating miRNAs as non-invasive biomarkers for myocardial stress and damage.
- Exploration of miRNA regulatory mechanisms in cardiotoxicity.
Main Results:
- Exosomal miRNAs are stable in biological fluids and can reflect early myocardial stress and damage.
- miRNAs offer earlier detection of subclinical cardiac changes compared to traditional biomarkers.
- Exosomal miRNAs possess diagnostic potential and therapeutic possibilities for cardiotoxicity.
Conclusions:
- Exosomal miRNAs are promising non-invasive biomarkers for the early diagnosis of cardiotoxicity.
- Understanding exosomal miRNA expression is crucial for developing personalized cardioprotective strategies.
- Exosomal miRNAs can aid in minimizing cardiovascular complications during cancer therapy.
Related Concept Videos
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
MicroRNAs
MicroRNAs

